Results 61 to 70 of about 111,750 (162)
Haematologica, 2015 Hepatitis C virus has been found to be associated with B-cell non-Hodgkin lymphomas, mostly marginal zone lymphomas and diffuse large B-cell lymphoma. Deregulation of signaling pathways involved in normal marginal zone development (NOTCH pathway, NF-κB ...
Luca Arcaini +23 more
doaj +1 more source
Guidelines for the management of diffuse large B‐cell lymphoma [PDF]
British Journal of Haematology, 2016 1Department of Haematology, Queen Elizabeth Hospital, Birmingham 2Department of Clinical Oncology, Christie Hospital, Manchester 3Department of Nuclear Medicine, Guys and St Thomas’ Hospitals, London 4Department of Haematology, West of Scotland Cancer Centre, Glasgow 5Department of Medical Oncology, Christie Hospital, Manchester 6Department of ...
Chaganti, Sridhar +9 more
openaire +3 more sources
MicroRNAs in diffuse large B-cell lymphoma
Oncology Letters, 2015 The aberrant expression of microRNAs (miRs) has a significant impact on the biological characteristics of lymphocytes, and is important in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). It has been demonstrated, using miR profiling and detecting distinct miR signatures, that certain miRs may accurately distinguish different subtypes and ...
Huiyun, Ni +4 more
openaire +3 more sources
Haematologica, 2008 Background The tumor microenvironment is important for the behavior of cancer. We assessed the distribution and biological significance of FOXP3+ regulatory T-cells (Treg) in lymphomas.Design and Methods The absolute number of intratumoral FOXP3+ cells ...
Alexandar Tzankov +5 more
doaj +1 more source
Treatment of Diffuse Large B-Cell Lymphoma
Journal of Clinical and Experimental Hematopathology, 2016 Diffuse large B-cell lymphoma (DLBCL) comprises a heterogeneous group with pathophysiological, genetic and clinical features. Many patients can be cured with R-CHOP therapy, which is the current standard regimen. Despite recent progress in improving patient survival, the 40% survival of DLBCL patients remains poor.
openaire +3 more sources
A Case of a Rapidly Progressive Small Bowel Lymphoma with High Ki-67 Expression
The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2017 Primary intestinal lymphoma is a rare disease. It accounts for approximately 1∼4% of gastrointestinal malignancy. Extranodal lymphoma of the intestine mainly arises from B cells.
Jiyeon Yoo +7 more
doaj +1 more source
Treatment of Diffuse Large B Cell Lymphoma
The Korean Journal of Internal Medicine, 2012 Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in all countries and all age groups. DLBCL is potentially curable, and the outcome of patients with DLBCL has completely changed with the introduction of therapy involving the monoclonal antibody rituximab in combination with chemotherapy.
openaire +2 more sources
Diagnosis and treatment of diffuse large B-cell lymphoma
Swiss Medical Weekly, 2012 Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant lymphoma in the Western world. It has an aggressive natural history, with a median survival of less than one year if left untreated. Immunochemotherapy regimens, consisting of the anti-CD20 antibody rituximab typically in combination with cyclophosphamide ...
Mey, U +8 more
openaire +3 more sources
Haematologica, 2017 Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinositol
Anas Younes +11 more
doaj +1 more source
Clinical Case Reports, 2019 Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous group of lymphomas which require multiagent therapy for remission induction and are associated with relapse in more than 40% of patients.
Lainey Flatow‐Trujillo +4 more
doaj +1 more source